Cagrisema vs Retatrutide: Comparing the Indexed Record
The practical distance between Cagrisema and Retatrutide shows up first in how much published methodology exists for each.
Compound profiles
Cagrisema in the indexed record
Cagrisema returns 71 indexed records on PubMed, a moderate record, alongside 30 registered studies on ClinicalTrials.gov.
Recent indexed work appears in BMJ, Nat Med.
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis — BMJ, 2024. PMID: 38286487
- Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial — Nat Med, 2024. PMID: 38914124
Retatrutide in the indexed record
Retatrutide returns 180 indexed records on PubMed, a moderate record, alongside 34 registered studies on ClinicalTrials.gov.
Journals represented in the current index include Nat Med.
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial — Nat Med, 2024. PMID: 38858523
Classification and why it matters
Cagrisema and Retatrutide sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for Cagrisema describes conditions validated for Cagrisema: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to Retatrutide without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
Side-by-side research profile
| Parameter | Cagrisema | Retatrutide |
|---|---|---|
| PubMed indexed records | 71 | 180 |
| Registered studies (ClinicalTrials.gov) | 30 | 34 |
| Literature depth | Moderate | Moderate |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
How the literature differs
The indexed record is not symmetrical between these two compounds. Retatrutide carries 109 more indexed records than Cagrisema, which means published methodology, characterisation data and replication attempts are more readily located for Retatrutide. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (30 vs 34) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Selecting between them for a study design
Cagrisema and Retatrutide are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (Retatrutide) generally offers more methodological precedent.
Verification and documentation
What is in the vial is established by lot-specific analytics, not by label text. HPLC gives purity as a share of total peak area; mass spectrometry confirms the molecular weight matches the intended sequence. Neither substitutes for the other.
Physical handling notes
Both arrive lyophilised. Standard practice keeps the unopened vial at -20°C, protected from light, and defers reconstitution until the point of use. Solution-phase stability is the limiting factor in most protocols, not powder-phase stability.
Repeated freezing and thawing is the most common avoidable source of degradation.
Frequently asked questions
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
Are Cagrisema and Retatrutide the same compound?
No. They are structurally distinct research compounds with separate literature records — 71 indexed records for Cagrisema and 180 for Retatrutide.
Which of Cagrisema or Retatrutide has more published research?
Retatrutide, with 180 indexed PubMed records against 71.
Related references
- Retatrutide — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.